Lazard Frères Gestion’s AbbVie ABBV Stock Holding History

Lazard Frères Gestion’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,200	Closed	-$218K	–	94
2024 Q1	$218K	Sell	1,200 -200	-14%	-$34.5K	0.01%	75
2023 Q4	$216K	Hold	1,400	–	–	0.01%	78
2023 Q3	$213K	Buy	+1,400	New	+$206K	0.01%	78

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Lazard Frères Gestion's ABBV Position: Q2 2024 in Review

Lazard Frères Gestion sold out of AbbVie (ABBV) in Q2 2024, closing a stake of 1,200 shares — an estimated $218K sold.

Lazard Frères Gestion first reported a position in ABBV in Q3 2023 and held it in 3 quarters. The position peaked at $218K in Q1 2024. 3,364 funds tracked by Wall St. Rank hold ABBV as of Q2 2024.

Lazard Frères Gestion reported no remaining AbbVie position as of Q2 2024 after selling out during the quarter.
Lazard Frères Gestion sold 1,200 AbbVie shares in Q2 2024, an estimated $218K.
Lazard Frères Gestion first reported a position in AbbVie in Q3 2023 and held it in 3 quarters.
Lazard Frères Gestion's AbbVie position peaked at $218K in Q1 2024.
3,364 funds tracked by Wall St. Rank held AbbVie as of Q2 2024.

Based on Lazard Frères Gestion's 13F filing for Q2 2024, filed 29 Jul 2024.